Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now OTC Markets OTCPK - Delayed Quote • USD ALK-Abelló A/S (AKBLF) Follow Compare 19.90 0.00 (0.00%) At close: April 7 at 4:00:00 PM EDT Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for AKBLF 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: AKBLF View More All News Press Releases SEC Filings Grant of share-based long-term incentive instruments to members of the Board of Management and key employees Annual General Meeting in ALK-Abelló A/S held on 13 March 2025 ACARIZAX® approved in Canada for treatment of young children Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy FDA approves ODACTRA® for the treatment of house dust mite allergy in young children Alk-Abello AS (AKBLF) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Annual General Meeting in ALK-Abelló A/S on 13 March 2025 Annual report 2024: ALK delivers 15% sales growth with profits up 65% Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025 ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system Related Tickers AKESF Akeso, Inc. 8.30 -0.84% ZEAL.CO Zealand Pharma A/S 410.40 -3.71% GUBRA.CO Gubra A/S 360.00 -3.49% BAVA.CO Bavarian Nordic A/S 140.15 -2.10% IMVT Immunovant, Inc. 14.39 -1.30% GMAB.CO Genmab A/S 1,234.00 -1.40%